␣ 1 -MICROGLOBULIN (A1M) is a 26-kDa globular protein within the lipocalin family (2, 3, 4, 10, 15, 23) . It is widely expressed in vertebrates, including humans, and is predominantly synthesized in the liver. After synthesis, A1M is secreted into plasma and distributes throughout the extracellular space. Approximately 50% of endogenously produced protein circulates in its native form (26 kDa, ϳ10 -20 g/ml plasma), with the remainder binding to other circulating proteins, most notably IgA (8, 9) . Free A1M is rapidly filtered by the kidney, with a plasma half-life of ϳ2-15 min. As predicted by their larger molecular masses, A1M-protein complexes are cleared more slowly, with plasma half-lives of ϳ2 h (1, 16) .
After glomerular filtration, A1M undergoes avid endocytosis by proximal tubule cells followed by its intracellular catabolism (1, 16) . As a result, only small amounts of A1M are normally excreted in urine. However, in the presence of acute tubular injury, a relative failure of proximal tubule protein reabsorption occurs, causing increased urinary A1M excretion (12, 29) . Thus, as with other low-molecular-weight proteins, e.g., ␤ 2 -microglobulin, increased urinary A1M concentrations can serve as a marker of acute tubular damage. Furthermore, under conditions of reduced glomerular filtration rate, A1M plasma concentrations rise and correlate with plasma creatinine concentrations (12, 15) . Thus, like cystatin C (another lowmolecular-weight protein), plasma A1M levels can serve as an indirect measure of glomerular filtration rate (5, 12) .
Beyond its function as a potential indicator of acute or chronic renal dysfunction, A1M has been reported to have potent antioxidant activities (e.g., Refs. 2, 3, 10, 20, and 25). Part of this action stems from its ability to bind (2:1) prooxidant free heme within the circulation or tissues. It then delivers it to the kidney for degradation and/or urinary elimination (15, 21) . A1M may also function as a free radical reductase/free radical scavenger, implying that it has multifunctional antioxidant properties. Finally, A1M has been reported to bind to immunomodulatory cells (B and T cells, natural killer cells, and polymorphonuclear cells) and potentially inhibit their proinflammatory effects (26) .
Given these actions, there has been considerable interest in developing recombinant A1M (rA1M) for use as a renal antioxidant and, potentially, as an anti-inflammatory agent (3, 10, 26) . Most attention in this area has focused on experimental studies of preeclampsia in which the placenta releases fetal hemoglobin/free heme into the maternal circulation, where it can potentially incite renal vascular, glomerular, and tubular disease (6, 7, 11, 18) . That A1M may exert a protective role in this situation is supported by a report (28) showing that rA1M administration improves glomerular sieving defects in a sheep preeclampsia model. Whether rA1M might attenuate nonpreeclampsia-associated renal oxidant stress and the potential development of acute kidney injury (AKI) remain unknown.
The purpose of the present investigation was to obtain "proof of concept" that rA1M is a potent and useful antioxidant agent and, as such, mitigates heme/"catalytic" Fe-driven oxidant renal disease. To this end, we evaluated rA1M as an in vitro renal tubular cell antioxidant against 1) free hemin, 2) free Fe 2ϩ , 3) Fenton reagents (Fe ϩ H 2 O 2 ), 4) myoglobin, 5) antimycin A/Ca 2ϩ ionophore, and 6) hypoxia-mediated injuries. To assess the in vivo antioxidant/antiheme activities of A1M, its impact on 1) various severities of the glycerol model of myohemoglobinuria, 2) purified myoglobin injection, and 3) endotoxemia were tested in mice. Finally, because A1M, like neutrophil gelatinase-associated lipocalin (NGAL), is a mem-ber of the lipocalin family, we assessed whether myohemoglobinuria-mediated oxidant stress upregulates A1M expression in the kidney and/or liver, with the latter being the dominant site of A1M generation under normal physiological conditions. The results of these broad ranging experiments form the basis of this report.
METHODS

Human Proximal Tubule (HK-2) Cell Culture Experiments
General conditions. HK-2 cells, derived from a normal human kidney, were grown in keratinocyte serum-free medium supplemented with pituitary extract, as previously described (22) . All cells were passaged in T75 flasks. For experimentation, cells were recovered by trypsinization and seeded into 12-or 96-well Costar plates. Cell injury after treatments was assessed either by measuring percent lactate dehydrogenase (LDH) release using 12-well plates or percent cellular uptake of 4,5-(dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) using 96-well plates. In this regard, MTT uptake directly correlates with the number of viable cells (22) .
Hemin toxicity. Hemin is an iron-containing protoporphyrin, similar to that present in hemoglobin and myoglobin, and exerts a marked prooxidant effect due to free radical generation. As such, it can be used experimentally to simulate heme protein cytotoxicity. To this end, cells were seeded into 12-and 96-well plates. Four hours later, human rA1M (provided by A1M Pharma, "variant 35") was added to achieve a 0, 1, 5, or 10 M concentrations. One hour after rA1M addition, cells were either left under control conditions or challenged with 30 M hemin (H-2375, Sigma, St. Louis, MO). Approximately 18 h later, cell injury was gauged by either LDH release or MTT uptake.
Hemin toxicity: albumin versus A1M effects. Albumin, like A1M, has the capacity to bind free heme, forming methemalbumin (e.g., Ref. 9). Thus, we compared the relative impact of BSA versus A1M on hemin toxicity. HK-2 cells were treated as noted above with either 10 M rA1M or with 5 or 10 M BSA. [Note that because BSA is ϳ2 times the molecular weight of A1M, the 5 M BSA dose provided the approximate same total milligram of protein addition as the 10 M A1M dose.] After overnight incubations, the extent of hemin-induced cell injury was assessed by MTT uptake.
Hemin toxicity: effects of bovine serum. To ascertain whether serum could reproduce the protective effect of BSA, the above experiment was repeated, substituting 10% bovine serum. A more severe insult (50 M hemin rather than 30 M as above) was used. Cell injury was determined by percent LDH release.
Fe 2ϩ -mediated oxidative stress and ATP depletion-mediated cell injury. To ascertain whether A1M could block catalytic Fe toxicity, HK-2 cells were challenged with 10 M ferrous ammonium sulfate with the Fe complexed to equimolar hydroxyquinoline [a siderophore that facilitates intracellular Fe access (36) ]. Additional wells were exposed to an ATP depletion/cellular calcium overload challenge [5 M A23187 (Ca 2ϩ ionophore) ϩ 7.5 M antimycin A ϩ 20 mM 2-deoxyglucose (CAD)], as previously described in detail (14) . These challenges were added 1 h after rA1M (10 M) or vehicle addition. The following day, the extent of cell injury was assessed by LDH release and MTT uptake.
To ascertain whether a longer preincubation period with rA1M might confer a greater protective effect than the above used 1-h preincubation, the above experiment was repeated with the exception that rA1M or its vehicle were added ϳ18 h before imposing the Fe-hydroxyquinoline (FeHQ) or CAD challenge. Cell injury was assessed ϳ18 h later by percent LDH release and percent MTT uptake.
Fenton reagent-mediated toxicity. HK-2 cells were incubated with 10 M rA1M or its vehicle. One hour later, cells were challenged with the following Fenton reaction reagents: ferrous ammonium sulfate (5 M) ϩ ascorbic acid (50 M) ϩ H 2O2 (10 M) . Approximately 18 h later, cell injury severity was assessed by LDH release and MTT uptake. To assess potential protection with a more severe Fenton challenge, the above experiment was repeated by increasing each of the Fenton reagents fivefold versus what was used above.
Myoglobin-mediated toxicity. HK-2 cells grown in 96-well plates were incubated for 1 h with either 5 or 10 M rA1M. Control cells were incubated with rA1M vehicle. Cells were then challenged with horse skeletal muscle myoglobin (5 mg/ml, Mb0360, Sigma Chemical, Ref. 13) or left under control incubation conditions. Eighteen hours later, cell injury was assessed by MTT cell uptake, as previously described (13) .
Animal Experimentation
All in vivo experiments were conducted with male 30-to 40-g CD-1 mice obtained from Charles River Laboratories (Wilmington, MA) and maintained under normal vivarium conditions with free food and water access. The experimental protocols were approved by the institution's Institutional Animal Care and Use Committee in concordance with National Institutes of Health guidelines. All terminal experiments were conducted under deep pentobarbital anesthesia (ϳ50 mg/kg administered as an intraperitoneal injection).
Effects of Exogenous A1M Administration on Responses to
Glycerol-Induced AKI Severe AKI protocol (9 ml/kg glycerol injection). Because glycerolinduced rhabdomyolysis causes AKI via heme Fe-mediated oxidant stress (30, 31) , we tested whether exogenous A1M can mitigate this AKI model. To this end, six mice received a tail vein injection of human rA1M (7 mg/kg, "Enza 14," A1M Pharma) at the time of 9 ml/kg im glycerol injection (50% glycerol, administered in equally divided hindlimb injections). The glycerol injection was done under light isoflurane anesthesia. Two hours after glycerol injection, a second rA1M dose (7 mg/kg) was administered. The rA1M dosage was based on studies that demonstrated that 4 -6 mg/kg rA1M mitigates proteinuria in rat and sheep models of preeclampsia (7, 25, 28) . Three glycerol-treated mice that received vehicle injections instead of rA1M served as controls. Eighteen hours later, mice were anesthetized with pentobarbital and euthanized by phlebotomy via the inferior vena cava. AKI severity was assessed by blood urea nitrogen (BUN) and plasma creatinine concentrations. Additionally, plasma LDH levels were measured as a general marker of muscle, kidney, and hepatic injury severity (35) .
Modest AKI protocol (8 ml/kg glycerol injection). To assess whether rA1M might mitigate a more modest renal insult, the above experiment was repeated exactly as described above with the exception that a lower glycerol dose (8 ml/kg) that induces less renal injury than 9 ml/kg was administered. AKI severity at 18 h after glycerol injection was assessed as described above.
Mild renal injury protocol (4 ml/kg glycerol injection). The above protocol was repeated with the following two exceptions: 1) mice received 4 ml/kg glycerol injection and 2) at 4 h (rather than 18 h) after glycerol injection, mice were euthanized (n ϭ 6 glycerol-treated mice, half with either A1M or vehicle treatment). The impact of glycerol-induced myohemoglobinuria on renal homeostasis was assessed by measuring renal cortical heme oxygenase (HO)-1 mRNA, monocyte chemoattractant protein (MCP)-1 mRNA, and NGAL mRNA, all of which are highly redox-sensitive genes (17, 34, 35) . BUN and plasma creatinine concentrations at 4 h after glycerol injection were also assessed. In addition, NGAL protein concentrations in both renal cortical samples and terminal urine samples (obtained from the bladder) were determined by ELISA (34, 35) . The rationale for this 4 h after 4 ml/kg glycerol administration experiment was to determine whether the two rA1M doses administered during this timeframe might mitigate early, mild renal injury, as assessed using highly sensitive mRNA biomarkers of oxidative stress.
Minimal renal injury protocol (2 ml/kg glycerol injection).
To further reduce the severity of AKI and hence potentially bring out a protective effect of A1M, the above experiment was repeated exactly as described above with the exception that a 2 ml/kg glycerol dose was used.
Effects of A1M Administration on Purified Myoglobin-Induced Oxidant Stress
Because the glycerol model of AKI involves pathogenic pathways in addition to heme protein toxicity [e.g., renal hypoperfusion (30)], the potential effect of rA1M on purified heme toxicity was assessed. To this end, six mice received a tail vein injection of horse skeletal muscle myoglobin (Mb-0360, Sigma, 1 mg in 100 l saline). Immediately thereafter, a tail vein injection of either rA1M (7 mg/kg) or vehicle was administered (n ϭ 3 mice each). The rA1M or vehicle injections were repeated 2 h later. At 4 h after myoglobin injection, mice were anesthetized, and the kidneys were removed and extracted for cortical RNA and protein. HO-1, MCP-1, and NGAL mRNA and NGAL protein levels were measured and compared between the two groups and with values from nonmyoglobin-injected controls (n ϭ 6 mice). Urine NGAL levels were also assessed. 
Effect of A1M on Lipopolysaccharide-Induced Renal Stress
Because endotoxemia mediates its toxic effects in part via oxidative stress (e.g., Ref. 19) , the potential ability of A1M to mitigate these responses was addressed. Eight mice were injected with 10 mg/kg Esherichia coli lipopolysaccharide (LPS; 0111:B4, L-2630, Sigma Chemical, stock solution, 1 mg/ml saline, administered intraperitoneally). Half of the mice received 7 mg/kg rA1M (via the tail vein) at the time of LPS injection and 2 h thereafter. The remaining mice received vehicle injection. At 4 h after LPS administration, mice were anesthetized with pentobarbital, and the kidneys were removed. Renal cortical levels of TNF-␣, MCP-1, and NGAL mRNA were measured and compared with values observed in normal renal tissues (n ϭ 6). BUN levels were also assessed.
Isolated Proximal Tubule Experiments
Mice were injected with either 7 mg/kg rA1M or its vehicle (n ϭ 3 mice each). Two hours later, mice were anesthetized, the kidneys were removed, and cortical proximal tubules were extracted by process of collagenase digestion and differential Percoll centrifugation, as previously described (32) . The tubule preparations were divided into three aliquots; they were placed in 10-ml Erlenmeyer flasks in a 37°C shaking water and incubated under one of the following conditions: 1) control incubation (95% O 2-5% CO2), 2) hypoxic conditions (95% N2-5% CO2), or 3) with the addition of FeHQ (25 M). After 30-min incubations, the severity of cell injury with and without prior A1M treatment was assessed by percent LDH release.
A1M Expression After Myohemoglobinuric Challenge
Given that A1M is a member of the lipocalin protein family, we assessed whether it, like NGAL, is upregulated in response to AKI. To this end, 12 mice were briefly anesthetized with isoflurane and then subjected to 9 ml/kg im glycerol injection. At either 4 h (n ϭ 4 mice) or 18 h (n ϭ 8 mice) after glycerol injection, mice were deeply anesthetized with pentobarbital, the abdominal cavities were opened, . Equimolar bovine albumin (Alb) and 10% bovine serum induce complete protection against hemin toxicity, as assessed by percent LDH release. The above experiments were repeated but the effects of albumin, 10% bovine serum, and A1M were compared against 50 M hemin toxicity. Equal and complete protection against hemin toxicity were observed with the three treatments. http://ajprenal.physiology.org/ terminal blood samples were obtained from the vena cava, and the kidneys and pieces of the liver were resected and iced. For those mice euthanized at 18 h after glycerol injection, a terminal urine sample was also obtained (by bladder compression). Renal cortical and hepatic tissue samples were extracted for RNA and protein. All samples were analyzed for mouse A1M mRNA by RT-PCR (A1M primers: 5=-GCAATCTCCCCATAGTCCAA-3 and 5=-CTAC-CCTCTGGCTTGCAGAC-3 and GAPDH primers: 5=-CTGC-CATTTGCAGTGGCAAAGTGG-3= and 5=-TTGTCATGGATGAC-CTTGGCCAGG-3=). NGAL mRNA levels in the renal cortex and liver were assessed for comparison (33, 34) . Plasma samples were assayed for BUN and creatinine concentrations. In addition, from these glycerol-treated mice, three randomly selected renal, hepatic, plasma, and urine samples were assayed for mouse A1M protein levels using a commercially available ELISA (abx051183, Abbexa, Cambridge, UK). All values were compared with results obtained in equal numbers of nonglycerol-injected controls.
A1M mRNA Levels After Unilateral Ischemia-Reperfusion Injury
To further assess the potential impact of AKI on A1M gene expression, A1M mRNA levels were assessed after unilateral ischemia-reperfusion injury (27, 34, 35) . To this end, four mice were anesthetized with pentobarbital and subjected to 30 min of left renal pedicle occlusion (27, 32, 34) . Approximately 18 h later, mice were reanesthetized, both kidneys were resected, and renal cortical RNA samples were obtained and analyzed for A1M mRNA, as described above. The postischemic results were compared with those observed in the uninjured right (contralateral) kidney and in kidney samples obtained from four normal mice.
Mouse Renal Cortical and Plasma rA1M Detection by Western Blot Analysis
Six mice received two injections of rA1M 2 h apart. Two hours after the second injection, renal cortical, plasma, and urine samples were obtained. Samples from six normal mice were used as controls. The cortixes underwent protein and RNA extraction (vide infra). Plasma, urine, and renal cortical protein samples as well as isolated proximal tubule protein extracts from rA1M-treated and control mice, as described above, were probed for human rA1M by Western blot analysis using a previously described method (34, 38) . The antihuman A1M antibody was obtained from A1M Pharma.
Potential rA1M Effects on Biomarker mRNAs Independent of Superimposed Injury
To determine if rA1M independently impacted HO-1, MCP-1, and NGAL mRNA levels, renal cortical RNA samples were extracted from the above-described mice (used for Western blot analysis). They were probed for HO-1, MCP-1, and NGAL mRNA, and the values for the rA1M-treated versus control mice were compared.
Calculations and Statistics
All values are presented as means Ϯ SE. Statistical comparisons were made by a Student's unpaired t-test. Significance was judged by P Ͻ 0.05. All in vivo experiments used 3-6 mice/group. If multiple comparisons were made, a Bonferroni correction was applied. Cell culture experiments were repeated two to four times with 4 wells/treatment.
RESULTS
HK-2 Cell Culture Experiments
A1M incubation/hemin challenge. rA1M did not independently affect cell viability, as assessed by either MTT uptake (100ϩ% of controls) or percent LDH release (10%, the same as controls; Fig. 1 ). Hemin, in the absence of rA1M, induced marked cytotoxicity (ϳ70% reductions in MTT uptake and ϳ55% LDH release). rA1M induced potent, dose-dependent cytoprotection, totally blocking hemin-induced cell death at Ն5 M concentrations.
Albumin (BSA) versus A1M effects on hemin-induced toxicity. The hemin challenge lowered MTT uptake by ϳ65% (Fig. 2) . Although 10 M rA1M was, once again, able to completely block this toxicity, the same degree of protection resulted for equimolar 10 (M) or subequimolar (5 M) BSA addition. As shown in Fig. 3 , 50 M hemin caused 55% LDH release. rA1M addition completely blocked this toxicity (reducing LDH release to ϳ10%, comparable with control incubation). Hemin toxicity was again eliminated by either BSA or 10% serum addition.
FeHQ and ATP Depletion-Induced Cell Challenge
One-hour preexposure to 5 m rA1M. Exposure of HK-2 cells to either FeHQ or CAD induced significant LDH release compared with control incubated cells (Fig. 4, left) . In both cases, rA1M treatment failed to confer a protective effect. Paradoxically, both forms of cell injury were modestly in- . A1M treatment failed to protect against glycerol-induced acute kidney injury (AKI). AKI was induced by either 8 or 9 ml/kg glycerol injection with either vehicle injection twice (controls) or two doses of A1M (injected immediately after glycerol administration and 2 h later). By 18 h after glycerol injection, moderate to severe renal failure resulted, as assessed by blood urea nitrogen (BUN) and plasma creatinine levels. A1M failed to exert a protective effect. Glycerol also induced marked elevations in plasma LDH levels (a marker of renal/extrarenal injuries), and, again, no diminution of injury was observed. The horizontal lines represent mean normal BUN, creatinine, and LDH concentrations. As markers of renal injury/oxidant stress, redox-sensitive mRNAs [heme oxygenase (HO)-1, neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemoattractant protein (MCP)-1] and renal cortical/urinary NGAL protein levels were measured. Glycerol increased HO-1 mRNA and NGAL mRNA and protein expression, but in no case was recombinant ␣1-microglobulin (rA1M)-mediated protection observed. Paradoxically, rA1M significantly increased MCP-1 mRNA levels, suggesting a slight prooxidant effect (P values against the glycerol alone treatment group). BUN, blood urea nitrogen; NS, not significant. The same markers of renal injury/oxidant stress shown in Table 1 were used after a 2 ml/kg glycerol challenge. Again, glycerol increased HO-1 mRNA and NGAL mRNA levels, but these increases were not diminished by rA1M treatment. MCP-1 mRNA levels did not rise in response to the 2 ml/kg glycerol challenge. However, rA1M showed a tendency to raise postglycerol MCP-1 mRNA levels, as per Table 1 (P values against the glycerol alone treatment group).
creased by rA1M addition, despite the fact that rA1M had no independent effect on LDH release. Although not shown, both FeHQ and CAD challenges caused Ͼ95% reductions in MTT uptake, and no diminution of this injury was observed with rA1M addition.
Overnight preexposure to 10 m rA1M. When HK-2 cells had a preincubation with 10 M rA1M for 18 h (vs. 1 h, as used above), a significant worsening of both FeHQ-and CAD-induced injury was again observed, as assessed by LDH release (Fig. 4,  right) . This was despite the observation that the 18-h rA1M exposure, by itself, led to no increase in LDH release. Although not shown, comparable data were obtained by MTT assay, where a worsening of both FeHQ-and CAD-induced injury was observed (15 Ϯ 0.07% vs. 8.9 Ϯ 0.03% MTT uptake after Fe and 15 Ϯ 1.8% vs. 8.8 Ϯ 1.4% MTT uptake after CAD ofr control vs. A1M treatment, respectively, P Ͻ 0.01).
Fenton reagent-mediated toxicity. The Fenton reagents evoked dose-dependent cytotoxicity, as assessed by both MTT uptake and LDH release (Fig. 5) . In no instance was a reduction in cell injury observed with 10 M rA1M addition.
HK-2 cell myoglobin toxicity. Myoglobin addition induced HK-2 cytotoxicity, as manifested by a 39 Ϯ 1% reduction in MTT uptake (not shown). A1M (5 M) exerted a minimal protective effect (35 Ϯ 1% reduction in MTT uptake, P Ͻ 0.001). However, increasing the A1M concentration to 10 M failed to evoke a greater protective influence (45 Ϯ 1% vs. 42 Ϯ 2% reduction in MTT uptake, P Ͻ 0.01). This minimal protection was likely due to rA1M binding of small amounts of free hemin in the myoglobin preparation (Sigma).
A1M Administration for Glycerol-Induced AKI
Severe and moderate AKI. As shown in Fig. 6 , glycerol injection caused either moderate (8 ml/kg) or severe (9 ml/kg) AKI, as denoted by increases in BUN and creatinine concentrations. rA1M administration exerted no discernible protective effect, given that both BUN and creatinine levels were slightly higher, rather than lower, with therapy (analogous to the in vitro FeHQ and CAD experimental results). As shown in Fig. 6 , right, A1M also failed to alter plasma LDH concentrations, an integrated marker of muscle, hepatic, and renal injury (35) .
Mild AKI, as assessed 4 h after 4 ml/kg glycerol injection.
As expected, by 4 h after 4 ml/kg glycerol injection, only minimal, nonsignificant, increases in BUN and plasma creatinine values were observed (Table 1) . Marked increases in redox-sensitive HO-1 and NGAL gene expression resulted, as denoted by ϳ10-fold elevations in their mRNA levels. rA1M treatment for two times during this 4-h period failed to mitigate these mRNA increases. In contrast to HO-1 and NGAL mRNA, MCP-1 mRNA increases were not observed in glycerol-treated controls. However, a significant increase in MCP-1 mRNA was produced by rA1M treatment (P Ͻ 0.015). Finally, massive elevations of both renal cortical and urinary NGAL protein concentrations were observed 4 h after glycerol injection. These increases were not attenuated by rA1M treatment. Rather, ϳ30% (albeit nonsignificant) increases in renal cortical and urinary NGAL protein levels were observed with rA1M administration.
Minimal AKI, as assessed 4 h after 2 ml/kg glycerol injection. As shown in Table 2 , the results of these experiments recapitulated those noted with the 4 ml/kg glycerol dose, i.e., no azotemia, marked increases in HO-1 and NGAL mRNA levels, a failure of rA1M to attenuate these changes, and a modest rA1M induced-increase in renal cortical MCP-1 mRNA levels. As would be predicted from the lesser glycerol dose, smaller increases in renal cortical and urinary NGAL protein levels were observed (versus those resulting from the 4 ml/kg glycerol challenge). Again, no rA1M-mediated attenuation of NGAL protein levels was observed.
Effects of A1M Administration on Purified Myoglobin-Induced Oxidant Stress
Myoglobin injection induced mild renal injury, as indicated by increases in HO-1, MCP-1, and NGAL mRNA levels, but with maintenance of normal BUN and creatinine concentrations. In no case did rA1M treatment reduce these myoglobin-induced mRNA changes (Table 3) . Rather, there was a nonsignificant trend for rA1M to increase, rather than decrease, both MCP-1 mRNA and urinary NGAL protein levels.
Effect of A1M on LPS-Induced Renal Stress
LPS injection caused the expected increases in TNF-␣, MCP-1, NGAL, and HO-1 mRNA levels over control values (see Table 4 ). rA1M did not diminish these responses. Rather, and paradoxically, the trend was for increased, not decreased, gene expression in each test case. For example, two-to three- Although intravenous myoglobin did not increase BUN and creatinine concentrations at 4 h after injection, oxidant injury was implied by elevations of HO-1 and NGAL mRNA levels. rA1M treatment did not attenuate these responses and tended to increase, not decrease, MCP-1 mRNA expression (P ϭ 0.07). P values were evaluated against the glycerol alone treatment group. Table 4 Lipopolysaccharide (LPS) induced marked increases in each of the measured mRNAs. rA1M treatment tended to increase, not decrease, these biomarkers of inflammation/oxidant stress. Also, a significant increase in BUN values was observed, consistent with an exacerbation of LPS responses. P values were evaluated against the glycerol alone treatment group.
fold statistically significant increases in MCP-1 and NGAL mRNA levels were observed with LPS ϩ A1M versus LPS alone treatment. A slight but significant increase in BUN levels was also observed in the LPS ϩ rA1M treatment group compared with LPS-injected controls.
Isolated Proximal Tubule Experiments
As shown in Table 5 , FeHQ and hypoxia caused mild to moderate cell injury, as assessed by LDH release. In neither case did rA1M confer a cytoprotective effect. Mice received an intravenous rA1M injection, and, 2 h later, proximal tubules were isolated and incubated under control oxygenated conditions or subjected to either oxidant injury (Fe hydroxyquinoline) or hypoxia (95% N2-5% CO2; see text). After 30-min incubations, cell injury was assessed by percent lactate dehydrogenase release. Whereas both challenges caused significant increases in lactate dehydrogenase release, no difference was observed between control and rA1M-treated tubules. . Glycerol-mediated injury raised neutrophil gelatinase-associated lipocalin (NGAL) but not A1M mRNA levels in both the kidney and liver. NGAL and mouse A1M mRNA levels were measured at 4 and 18 h after 9 ml/kg glycerol (Glyc) injection. Marked NGAL mRNA increases were observed at both time points in both organs. However, no induction of A1M mRNA was seen at either times and in either organ (n ϭ 3 in each organ and at each time point). NS, not significant.
A1M and NGAL mRNA Responses to Glycerol Injection
Mouse A1M mRNA levels remained at control values in both the kidney and liver at both 4 h (Fig. 7, top) and 18 h (Fig.  7, bottom) after glycerol injection. This was despite the fact that severe AKI was induced, as assessed at the 18-h postglycerol injection time point (BUN: 138 Ϯ 6 mg/dl and creatinine: 1.88 Ϯ 0.16 mg/dl vs. control BUN: 26 Ϯ 1 and creatinine: 0.32 Ϯ 0.01). In contrast to mouse A1M mRNA, marked hepatic and renal NGAL mRNA induction was observed at both 4 and 18 h after glycerol injection (rising as much as 10-to 15-fold over values observed in control tissues). Thus, despite the fact that both A1M and NGAL are both within the lipocalin family, these findings are consistent with the concept that these two proteins are constitutively versus inducibly expressed, respectively. Further consistent with this view is that unilateral ischemia-reperfusion injury failed to increase A1M mRNA levels (data not shown).
A1M Protein Levels After Glycerol Injection
By 18 h after glycerol injection, an approximate doubling of murine renal cortical A1M protein concentrations and a fivefold increase in urinary murine A1M protein concentrations were observed (Fig. 8) . However, the fact that no increase in A1M mRNA was detected in the cortex implies that these renal cortical/urinary A1M increases were not due to increased renal A1M synthesis but rather to decreased A1M proximal tubule reabsorption, leading to partial A1M trapping within distal nephron segments and increased urine excretion [e.g., analogous to findings with increased renal/urinary hemopexin levels during AKI (33) ].
Mouse Renal Cortical and Plasma A1M Detection by Western Blot Analysis
The rA1M formulation used for in vivo experiments appeared as the expected ϳ26-kDa band ( Fig. 9; standard) . This same band was also apparent in urine samples obtained 2 h after the second A1M injection. Plasma samples from control mice demonstrated an ϳ22-kDa band, potentially representing cross reactivity of the anti-human A1M antibody with murine A1M. Plasma samples from rA1M-treated mice showed two bands: the 26-kDa band (representing human rA1M) and the presumptive cross-reacting mouse A1M band. Renal cortical samples as well as isolated proximal tubule samples showed either minimally detectable or no clear A1M bands (Fig. 9) . However, there were higher as well as lower molecular weigh bands, likely reflecting A1M degradation products.
Evaluation of Potential Independent rA1M Effects on Biomarker mRNAs
Two doses of rA1M had no significant independent impact on HO-1, MCP-1, or NGAL mRNA levels in normal mice (data not shown). Thus, the increases seen in the glycerol-and LPS-mediated AKI models were not attributable to an independent rA1M effect.
DISCUSSION
This study confirms that A1M can exert potent cytoprotective effects against hemin toxicity, at least when tested in an in vitro system. In part, this is likely due to direct hemin binding by A1M, which has two recognized heme-binding sites (21) . Thus, by complexing free heme, its ability to evoke oxidative injury is suppressed (10) . It has also been suggested that A1M can act as a free radical reductase and scavenger, thereby imparting additional cytoprotective effects (10) . However, based on the available data, we suggest that direct hemin binding was more likely responsible for the observed hemin toxicity blockade: 1) equimolar albumin, which also binds heme (forming methemalbumin), conferred equal protection compared with rA1M; 2) 10% normal bovine serum, which in addition to albumin contains large amounts of hemopexin [the most potent known heme binder (33) ], also induced hemin toxicity blockade; and 3) A1M failed to protect HK-2 cells from nonhemin-mediated forms of oxidant attack (e.g., catalytic Fe, Fenton reagents, and antimycin A). We cannot exclude the possibility that under different experimental . Glycerol-mediated injury increases A1M levels in the kidney and induces an increase in urinary A1M excretion without raising A1M plasma levels. Although glycerol did not appear to increase renal A1M production (no change in mRNA; see Fig. 7 ), increases in renal cortical and urinary A1M concentrations were observed at 18 h after glycerol injection (9 ml/kg). Thus, it is assumed that the increase in kidney and urine A1M likely resulted from decreased proximal tubule A1M reabsorption, increased distal delivery, partial trapping in medullary casts (see Fig. 9 ), and increased urinary A1M concentrations (n ϭ 4 per measurement).
circumstances, nonheme-binding antioxidant activities could take effect. For example, the possibility exists that relatively slow cellular HK-2 cell rA1M uptake could prevent rapid expression of its antioxidant properties. However, it is noteworthy that when cells were incubated with A1M for 18 h rather than 1 h before catalytic Fe or antimycin A challenges, a worsening of injury, rather than protection, was observed (as shown in Fig. 4 ). To test whether rA1M could evoke protection against in vivo oxidant stress, we undertook an expansive series of experiments using the glycerol model of rhabdomyolysis. After glycerol injection, both muscle necrosis and hemolysis result, leading to myohemoglobinemia/uria, free heme release, and heme iron-driven renal oxidative damage (30). Thus, were rA1M able to mitigate in vivo heme-driven oxidant injury, one would predict that it would do so in this model. However, when either moderate or severe AKI was induced with 8 or 9 ml/kg glycerol, respectively, no protection was observed, as gauged 18 h later by BUN and creatinine concentrations. We then questioned whether we were simply overwhelming the antioxidant actions of A1M with high-dose (8 or 9 ml/kg) glycerol injection. Thus, we reduced the glycerol dose to 2 or 4 ml/kg, and, 4 h later, renal injury was gauged by expression of redox-sensitive genes (17, 34, 35) . By 4 h after glycerol injection, increased HO-1 and NGAL mRNA levels were observed. Of note, both of these mRNAs directly correlate with the severity of renal injury/oxidative stress (27, 34, 35) . However, A1M failed to mitigate these increases. In contrast to HO-1 and NGAL, no increases in MCP-1 mRNA were observed by 4 h after low-dose glycerol injection. However, with A1M treatment, paradoxical MCP-1 mRNA increases were observed, suggesting a potential A1M-induced adverse effect. To test for potential A1M-mediated protection in a nonglycerol model of myoglobinuria, 0.5 mg purified myoglobin was injected with and without A1M treatment. Again, a lack of A1M-mediated protection, as assessed by a lack of reductions in either HO-1 or NGAL mRNA, and paradoxical increases in MCP-1 mRNA were observed. Finally, we tested whether endotoxemia, and its associated renal oxidative stress (19) , might be reduced by rA1M. However, a worsening of, rather than protection against, endotoxemia was observed (greater elevations of BUN, TNF-␣, MCP-1, and NGAL mRNA levels vs. those seen in LPS-injected controls). In summary, despite using four different doses of glycerol, purified myoglobin injection, and LPS administration, no evidence for rA1M-mediated protection was detected. Indeed, these in vivo results seemingly recapitulate the in vitro HK-2 cell data discussed above, i.e., where no protection against, and a potential exacerbation of, nonhemin-induced injuries occurred.
There are a number of potential explanations for why rA1M did not protect against in vivo oxidant injury, as described above. First, it is important to recall that albumin conferred equimolar protection to that produced by A1M and that plasma albumin is present at ϳ400 times the concentration of A1M. A similar situation exists for hemopexin, the most potent known free heme binder. Thus, it is likely that the heme binding capacity of A1M in blood is simply "swamped out" by much higher albumin/hemopexin levels. Second, it is noteworthy that injected rA1M has a plasma half-life of Ͻ15 min (1, 16) . Thus, only very short-lived plasma activity would be expected. Third, we observed that by 2 h after A1M injection, essentially none could be documented in the renal cortex or isolated proximal tubules. This implies rapid cellular catabolism and loss of A1M activity.
A more perplexing issue than a lack of protective activities (excluding in vitro hemin) is why rA1M seemingly exerted paradoxical adverse effects (e.g., worse HK-2 cell injury with nonhemin challenges and paradoxical in vivo increases of MCP-1 and/or NGAL mRNA). In this regard, a number of potential issues deserve consideration. First, endocytosis of filtered low-molecular-weight proteins has previously been demonstrated to exacerbate renal tubular injury due to increased plasma membrane recycling and membrane damage (37) . Second, administration of freely filtered low-molecular-weight proteins, in general, can provide substrate for luminal cast formation, thereby increasing tubule obstruction in this process. Third, if A1M were to bind free heme within the circulation, it would then deliver it to proximal tubules via filtration/endocytosis. Thus, with subsequent A1M catabolism, free heme, catalytic iron, or potential toxic proteasomal degradation products could be released within proximal tubule cells, thereby contributing to evolving oxidant damage. While the relative contributions of the above factors remain unknown, future indepth studies could be done to discriminate between these possibilities. Fig. 9 . Western blot analysis for rA1M after injection into mice. rA1M was administered twice, 2 h apart. Two hours after the end injection, plasma samples, renal cortical samples, isolated proximal tubule samples, and mouse urine were probed with anti-human A1M. All plasma samples from A1M-treated mice demonstrated two bands. The upper molecular weight band ran with the A1M standard (STD) reflected the injected rA1M. The lower band was seen in all A1M-treated mice as well as non-A1M-treated control mice and was presumed to represent endogenous mouse A1M with cross reactivity to the anti-human antibody. Mouse urine from A1M-treated mice showed a single band, which was not seen on control mouse urine, and presumptively reflects filtered and excreted rA1M. The mouse cortex and isolated proximal tubule segment protein extracts showed either a faint or no A1M band, but multiple presumptive degradative products were apparent. In summary, rA1M could be detected in rA1M-treated mice in both plasma and urine, but little was seen in the cortex/proximal tubules, presumably due to rapid intrarenal degradation.
It should be underscored that while we were not able to document any benefit of A1M administration in vivo, it remains possible that therapeutic efficacy might exist in other renal or nonrenal applications [e.g., glomerulonephritis or preeclampsia (28) ]. However, even if rA1M were used as a therapeutic for such indications, a number of major limitations would still exist. One of the most daunting would be rapid renal clearance, given the extremely short plasma half-life of A1M [ϳ2-15 min (1, 16) ]. Thus, to sustain plasma A1M or extrarenal concentrations at some pharmacologically relevant level, continuous infusion would seemingly be required. Furthermore, given the marked predominance of albumin and hemopexin in the circulation, it remains unclear as to whether the free heme-binding effects of rA1M could evoke a clinically meaningful therapeutic effect. Finally, after endocytosis, rapid renal catabolism would seemingly limit potential beneficial actions. In summary, these barriers would need to be overcome to successfully deploy rA1M as a clinical therapeutic agent.
